Literature DB >> 3965509

Platelet-induced neurogenic coronary contractions due to accumulation of the false neurotransmitter, 5-hydroxytryptamine.

R A Cohen.   

Abstract

The purpose of this study was to determine if 5-hydroxytryptamine released from aggregating platelets could be accumulated and released by canine coronary adrenergic nerves, and if the false neurotransmitter resulted in an abnormal response of the smooth muscle to nerve stimulation. Isometric tension was measured in rings of epicardial coronary suspended in organ chambers filled with physiological salt solution. The response to electrical stimulation or exogenously added norepinephrine was elicited after contraction with prostaglandin F2 alpha. Electrical stimulation and exogenous norepinephrine caused beta-adrenergic relaxation of control rings. However, after rings were exposed for 2 h to aggregating platelets or 5-hydroxytryptamine, electrical stimulation caused frequency-dependent contractions. These contractions were prevented by the serotonergic antagonists, cyproheptadine or ketanserin, or by the neuronal uptake inhibitor, cocaine. The relaxation caused by exogenously added norepinephrine was unchanged after exposure to platelets or 5-hydroxytryptamine, indicating that smooth muscle alpha- and beta-adrenergic responsiveness was unchanged. The electrically stimulated overflow of radiolabeled norepinephrine from superfused strips of coronary artery was not altered by prior exposure to 5-hydroxytryptamine, indicating that the effect of exposure on the response to electrical stimulation is primarily at smooth muscle serotonergic receptors. Canine coronary arteries accumulated and metabolized radiolabeled 5-hydroxytryptamine in vitro. The accumulation of 5-hydroxytryptamine was inhibited by cocaine or by adrenergic denervation with 6-hydroxydopamine but unaffected by removal of endothelium, indicating that the adrenergic nerves were the primary site of accumulation. Electrical stimulation of superfused strips of coronary artery preincubated with radiolabeled 5-hydroxytryptamine caused the release of the intact indoleamine; this was blocked by the neurotoxin, tetrodotoxin. These studies suggest that 5-hydroxytryptamine liberated from aggregating platelets may be accumulated by coronary adrenergic nerve endings. Upon its release from the nerves as a false transmitter, the amine can activate serotonergic receptors on the smooth muscle and reverse the action of the adrenergic nerves from dilator to constrictor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965509      PMCID: PMC423438          DOI: 10.1172/JCI111687

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Effects of moderate acidosis on adrenergic neurotransmission in canine saphenous veins.

Authors:  T J Verbeuren; W J Janssens; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1978-07       Impact factor: 4.030

2.  5-hydroxytryptamine and neurotransmitter release in canine blood vessels. Inhibition by low and augmentation by high concentrations.

Authors:  M A McGrath
Journal:  Circ Res       Date:  1977-10       Impact factor: 17.367

3.  Determination of 3H-norepinephrine and its metabolites in superfusate from isolated blood vessels.

Authors:  T J Verbeuren; E Coen; P M Vanhoutte
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-05

4.  Uptake, metabolism and efflux of 14 C-5-hydroxytryptamine in isolated perfused rat lungs.

Authors:  A F Junod
Journal:  J Pharmacol Exp Ther       Date:  1972-11       Impact factor: 4.030

5.  The accumulation of C14-serotonin in the guinea-pig vas deferens.

Authors:  N B Thoa; D Eccleston; J Axelrod
Journal:  J Pharmacol Exp Ther       Date:  1969-09       Impact factor: 4.030

6.  In vitro denervation of the portal vein and caudal artery of the rat.

Authors:  O Aprigliano; K Hermsmeyer
Journal:  J Pharmacol Exp Ther       Date:  1976-09       Impact factor: 4.030

7.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

8.  Acid metabolites of monoamines in avian brain; effects of probenecid and reserpine.

Authors:  L Ahtee; D F Sharman; M Vogt
Journal:  Br J Pharmacol       Date:  1970-01       Impact factor: 8.739

9.  Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of "preinfarction" angina.

Authors:  A Maseri; A L'Abbate; G Baroldi; S Chierchia; M Marzilli; A M Ballestra; S Severi; O Parodi; A Biagini; A Distante; A Pesola
Journal:  N Engl J Med       Date:  1978-12-07       Impact factor: 91.245

10.  Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.

Authors:  P D Hirsh; L D Hillis; W B Campbell; B G Firth; J T Willerson
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

View more
  5 in total

1.  Inhibitory effect of 5-hydroxytryptamine on penile erectile function in the rat.

Authors:  J P Finberg; Y Vardi
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  5-Hydroxytryptamine immunoreactivity is detectable in sympathetic nerve fibres in rat oral tissues.

Authors:  L I Norevall; L Matsson; S Forsgren
Journal:  Histochem J       Date:  1996-07

3.  Adenine nucleotides and 5-hydroxytryptamine released by aggregating platelets inhibit adrenergic neurotransmission in canine coronary artery.

Authors:  R A Cohen
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

4.  An amplifying effect of exogenous and neurally stored 5-hydroxytryptamine on the neurogenic contraction in rat tail artery.

Authors:  C Szabó; J E Hardebo; C Owman
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

Review 5.  A dialogue between the immune system and brain, spoken in the language of serotonin.

Authors:  Nicole L Baganz; Randy D Blakely
Journal:  ACS Chem Neurosci       Date:  2012-12-07       Impact factor: 4.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.